Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tofacitinib and baricitinib are the first orally available, small-molecule inhibitors of Janus kinase (JAK) enzymes to be approved for the treatment of RA. Tofacitinib is a selective JAK1, 3 inhibitor with less activity against JAK2 and TYK2 and baricitinib is a selective, oral JAK1, 2 inhibitor with moderate activity against TYK2 and significantly less activity against JAK3. Both drugs have undergone extensive phase III clinical trials in RA and demonstrated rapid improvements in disease activity, function and patient-reported outcomes as well as disease modification. Tofacitinib 5 mg bd, was approved by the Federal Drug Administration in 2012 for the treatment of RA in patients who are intolerant or unresponsive to MTX. An extended release formulation for the treatment of RA was approved by Federal Drug Administration in 2016. In 2017 the European Medicines Agency approved tofacitinib 5 mg bd in combination with MTX and baricitinib 4 mg and 2 mg once daily for the treatment of moderate to severe active RA in adult patients who are intolerant or unresponsive to one or more conventional synthetic DMARDs.

Original publication

DOI

10.1093/rheumatology/key225

Type

Journal article

Journal

Rheumatology (oxford)

Publication Date

01/02/2019

Volume

58

Pages

i17 - i26

Keywords

Janus kinase, baricitinib, efficacy, function, patient reported outcomes, rheumatoid arthritis, small-molecule kinase inhibitor, structural damage, symptoms and signs, tofacitinib, Antirheumatic Agents, Arthritis, Rheumatoid, Azetidines, Drug Therapy, Combination, Humans, Janus Kinase 1, Janus Kinase 2, Janus Kinase 3, Janus Kinase Inhibitors, Methotrexate, Piperidines, Pyrimidines, Pyrroles, Sulfonamides, Treatment Outcome